Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.78, read 2026-10-28
Ethical passes the values gate
Price38.28 USD
Fair value24.44
Ethical score70.0/100
Our investment reviews on this name
2026-10-15Read Markdown36.74+4.2% to today Accumulation gives way to Markdown with volume flow in agreement
2026-09-11Read Accumulation37.62+1.8% to today ✓Markup gives way to Accumulation first Accumulation read since July
2026-08-11Read Markup36.50+4.9% to today ✓Accumulation gives way to Markup
2026-07-02Read Accumulation35.09+9.1% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Rexford Industrial Realty, Inc. holds its Markup at $38.28. Consolidating, no directional conviction, held for 44 days.
As held on the ledger · 2026-10-27
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 44 days
Price at the screen
$38.28
Valuation
N/A trailing · 36.83 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.20
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
25.78%
Below 33%
Interest-bearing debt is just 25.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
2.93%
Below 49%
Money owed to the company is 2.9% of assets, under the 49% limit.
Pass
Revenue purity
2.21%
Below 5%
Only 2.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Rexford Industrial Realty, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 26%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when REXR's ethical verdict changes
Today REXR passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. The price runs 36.1% above the base estimate.
Third-party analyst targets: 16 covering, consensus Buy. The average target sits +4% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
California Warehouses Priced Well Beyond Their Worth
Picture a warehouse owner in Los Angeles trying to lock in space amid chronic shortages. Rexford Industrial Realty owns and repositions infill sites in that tight market, yet the shares sit at $37.46 against our fair value of $24.00. With revenue already down 3 percent and a forward multiple of 39.6 times earnings, the market is paying for growth that has stopped arriving.
The business clears a 23 percent profit margin and passes our ethical screen, yet return on equity sits at just 3 percent and the moat remains unproven. Sixteen analysts still rate the name a buy with a $40 median target, but those forecasts rest on assumptions that look detached from the current revenue trend and modest capital returns.
High valuations in cyclical property sectors often mark peak conditions rather than bargains. Currency or rate shifts could widen the gap between price and value further, and thin earnings power leaves little room for disappointment. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
REXR trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-22Markdown$36.37+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (16 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$36.37+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (16 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markdown$36.37-1.5%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (16 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markdown$36.91+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (16 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$36.91+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (16 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markdown$36.91+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (16 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markdown$36.91+0.5%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (16 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markdown · changed$36.74+0.0%Entry 8
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (16 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Accumulation$36.74+2.0%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (16 analysts) rates it buy, with a mean price target of $40.
2026-10-02Accumulation$36.02-4.3%Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (16 analysts) rates it buy, with a mean price target of $40.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
